149 related articles for article (PubMed ID: 17510383)
1. Attenuated expression of xeroderma pigmentosum group C is associated with critical events in human bladder cancer carcinogenesis and progression.
Chen Z; Yang J; Wang G; Song B; Li J; Xu Z
Cancer Res; 2007 May; 67(10):4578-85. PubMed ID: 17510383
[TBL] [Abstract][Full Text] [Related]
2. XPC deficiency leads to centrosome amplification by inhibiting BRCA1 expression upon cisplatin-mediated DNA damage in human bladder cancer.
Wang H; Huang Y; Shi J; Zhi Y; Yuan F; Yu J; Chen Z; Yang J
Cancer Lett; 2019 Mar; 444():136-146. PubMed ID: 30579971
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer.
Xu XS; Wang L; Abrams J; Wang G
J Hematol Oncol; 2011 Apr; 4():17. PubMed ID: 21507255
[TBL] [Abstract][Full Text] [Related]
4. Elevated and biallelic expression of p73 is associated withprogression of human bladder cancer.
Chi SG; Chang SG; Lee SJ; Lee CH; Kim JI; Park JH
Cancer Res; 1999 Jun; 59(12):2791-3. PubMed ID: 10383132
[TBL] [Abstract][Full Text] [Related]
5. Attenuated XPC expression is not associated with impaired DNA repair in bladder cancer.
Naipal KA; Raams A; Bruens ST; Brandsma I; Verkaik NS; Jaspers NG; Hoeijmakers JH; van Leenders GJ; Pothof J; Kanaar R; Boormans J; van Gent DC
PLoS One; 2015; 10(4):e0126029. PubMed ID: 25927440
[TBL] [Abstract][Full Text] [Related]
6. The initiative role of XPC protein in cisplatin DNA damaging treatment-mediated cell cycle regulation.
Wang G; Chuang L; Zhang X; Colton S; Dombkowski A; Reiners J; Diakiw A; Xu XS
Nucleic Acids Res; 2004; 32(7):2231-40. PubMed ID: 15107491
[TBL] [Abstract][Full Text] [Related]
7. Defining the function of XPC protein in psoralen and cisplatin-mediated DNA repair and mutagenesis.
Chen Z; Xu XS; Yang J; Wang G
Carcinogenesis; 2003 Jun; 24(6):1111-21. PubMed ID: 12807748
[TBL] [Abstract][Full Text] [Related]
8. Xeroderma pigmentosum group C gene expression is predominantly regulated by promoter hypermethylation and contributes to p53 mutation in lung cancers.
Wu YH; Tsai Chang JH; Cheng YW; Wu TC; Chen CY; Lee H
Oncogene; 2007 Jul; 26(33):4761-73. PubMed ID: 17325666
[TBL] [Abstract][Full Text] [Related]
9. Malignant melanoma cells acquire resistance to DNA interstrand cross-linking chemotherapeutics by p53-triggered upregulation of DDB2/XPC-mediated DNA repair.
Barckhausen C; Roos WP; Naumann SC; Kaina B
Oncogene; 2014 Apr; 33(15):1964-74. PubMed ID: 23604128
[TBL] [Abstract][Full Text] [Related]
10. Association between DNA repair gene polymorphisms and p53 alterations in Japanese patients with muscle-invasive bladder cancer.
Sakano S; Matsumoto H; Yamamoto Y; Kawai Y; Eguchi S; Ohmi C; Matsuyama H; Naito K
Pathobiology; 2006; 73(6):295-303. PubMed ID: 17374967
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of xeroderma pigmentosum group C decreases the chemotherapeutic sensitivity of colorectal carcinoma cells to cisplatin.
Zhang Y; Cao J; Meng Y; Qu C; Shen F; Xu L
Oncol Lett; 2018 May; 15(5):6336-6344. PubMed ID: 29616110
[TBL] [Abstract][Full Text] [Related]
12. p53 dysfunction by xeroderma pigmentosum group C defects enhance lung adenocarcinoma metastasis via increased MMP1 expression.
Wu YH; Wu TC; Liao JW; Yeh KT; Chen CY; Lee H
Cancer Res; 2010 Dec; 70(24):10422-32. PubMed ID: 21056989
[TBL] [Abstract][Full Text] [Related]
13. XPC epigenetic silence coupled with p53 alteration has a significant impact on bladder cancer outcome.
Yang J; Xu Z; Li J; Zhang R; Zhang G; Ji H; Song B; Chen Z
J Urol; 2010 Jul; 184(1):336-43. PubMed ID: 20488473
[TBL] [Abstract][Full Text] [Related]
14. Nucleotide excision repair factor XPC enhances DNA damage-induced apoptosis by downregulating the antiapoptotic short isoform of caspase-2.
Wang QE; Han C; Zhang B; Sabapathy K; Wani AA
Cancer Res; 2012 Feb; 72(3):666-75. PubMed ID: 22174370
[TBL] [Abstract][Full Text] [Related]
15. Expression of xeroderma pigmentosum complementation group C protein predicts cisplatin resistance in lung adenocarcinoma patients.
Lai TC; Chow KC; Fang HY; Cho HC; Chen CY; Lin TY; Chiang IP; Ho SP
Oncol Rep; 2011 May; 25(5):1243-51. PubMed ID: 21327329
[TBL] [Abstract][Full Text] [Related]
16. Loss of p73 induction in a cisplatin-resistant bladder cancer cell line.
Ono Y; Nonomura N; Harada Y; Fukui T; Tokizane T; Sato E; Nakayama M; Nishimura K; Takahara S; Okuyama A
Mol Urol; 2001; 5(1):25-30. PubMed ID: 11689148
[TBL] [Abstract][Full Text] [Related]
17. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
[TBL] [Abstract][Full Text] [Related]
18. The involvement of XPC protein in the cisplatin DNA damaging treatment-mediated cellular response.
Wang G; Dombkowski A; Chuang L; Xu XX
Cell Res; 2004 Aug; 14(4):303-14. PubMed ID: 15353127
[TBL] [Abstract][Full Text] [Related]
19. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
[TBL] [Abstract][Full Text] [Related]
20. p73 tumor-suppressor activity is impaired in human thyroid cancer.
Frasca F; Vella V; Aloisi A; Mandarino A; Mazzon E; Vigneri R; Vigneri P
Cancer Res; 2003 Sep; 63(18):5829-37. PubMed ID: 14522906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
